Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Authors
Keywords
-
Journal
Nature Reviews Gastroenterology & Hepatology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-22
DOI
10.1038/s41575-020-00366-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
- (2020) Sander Lefere et al. JOURNAL OF HEPATOLOGY
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Taurine protected As2O3-induced the activation of hepatic stellate cells through inhibiting PPARα-autophagy pathway
- (2019) Zhidong Wang et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Pioglitazone Therapy in Patients With Stroke and Prediabetes
- (2019) J. David Spence et al. JAMA Neurology
- Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
- (2019) Koutaro Yokote et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Efficacy and Safety of Pemafibrate in Patients with Type 2 Diabetes and Elevated Triglyceride levels: 52-Week Data From The PROVIDE Study
- (2019) Eiichi Araki et al. DIABETES OBESITY & METABOLISM
- Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes
- (2019) Ralph A DeFronzo et al. Diabetes & Vascular Disease Research
- Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
- (2019) Sven Francque et al. ADVANCES IN THERAPY
- Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis
- (2019) Oliver Krenkel et al. GUT
- Type 2 diabetes mellitus is a risk factor for progression of liver fibrosis in middle‐aged patients with nonalcoholic fatty liver disease
- (2019) Toshifumi Tada et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications
- (2019) Saumya Jayakumar et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
- (2019) Upendra Kaul et al. Cardiovascular Diabetology
- The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential
- (2019) Jean-Charles Fruchart et al. Cardiovascular Diabetology
- Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks
- (2019) Naveed Sattar et al. CIRCULATION
- Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
- (2019) Fernando Bril et al. DIABETES CARE
- Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD
- (2019) Mary E. Rinella et al. HEPATOLOGY
- Diabetes is Associated with Increased Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease
- (2019) Ju Dong Yang et al. HEPATOLOGY
- The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis
- (2019) Zobair M. Younossi et al. JOURNAL OF HEPATOLOGY
- Metabolic reprogramming in atherosclerosis: Opposed interplay between the canonical WNT/β-catenin pathway and PPARγ
- (2019) Alexandre Vallée et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Resolving the fibrotic niche of human liver cirrhosis at single-cell level
- (2019) P. Ramachandran et al. NATURE
- The integrative biology of type 2 diabetes
- (2019) Michael Roden et al. NATURE
- Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis
- (2018) Srilaxmi Kalavalapalli et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice
- (2018) Montserrat A. de la Rosa Rodriguez et al. BMC GENOMICS
- Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases
- (2018) Varman T. Samuel et al. Cell Metabolism
- Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone
- (2018) Lawrence H. Young et al. CIRCULATION
- Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
- (2018) Alessandro Mantovani et al. DIABETES CARE
- Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis
- (2018) Maria Apostolopoulou et al. DIABETES CARE
- Molecular actions of PPARα in lipid metabolism and inflammation
- (2018) Nadia Bougarne et al. ENDOCRINE REVIEWS
- PPAR Agonists and Metabolic Syndrome: An Established Role?
- (2018) Margherita Botta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study
- (2018) G. Hirschfield et al. JOURNAL OF HEPATOLOGY
- Lipotoxicity and the gut-liver axis in NASH pathogenesis
- (2018) Fabio Marra et al. JOURNAL OF HEPATOLOGY
- Pharmacotherapy for NASH: Current and emerging
- (2018) Monica A. Konerman et al. JOURNAL OF HEPATOLOGY
- Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
- (2018) Chris Estes et al. JOURNAL OF HEPATOLOGY
- Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate
- (2018) Benaïssa Boubia et al. JOURNAL OF MEDICINAL CHEMISTRY
- Enhanced MiR-711 transcription by PPARγ induces endoplasmic reticulum stress-mediated apoptosis targeting calnexin in rat cardiomyocytes after myocardial infarction
- (2018) Na Zhao et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications
- (2018) Ralf Weiskirchen et al. MOLECULAR ASPECTS OF MEDICINE
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith–Wiedemann syndrome: an international consensus statement
- (2018) Frédéric Brioude et al. Nature Reviews Endocrinology
- Triggering and resolution of inflammation in NASH
- (2018) Susanne Schuster et al. Nature Reviews Gastroenterology & Hepatology
- Interorgan Metabolic Crosstalk in Human Insulin Resistance
- (2018) Sofiya Gancheva et al. PHYSIOLOGICAL REVIEWS
- Nonalcoholic Fatty Liver Disease in Children
- (2018) Jake Mann et al. SEMINARS IN LIVER DISEASE
- Diet-Induced Circadian Enhancer Remodeling Synchronizes Opposing Hepatic Lipid Metabolic Processes
- (2018) Dongyin Guan et al. CELL
- The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
- (2018) Fan Hong et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial
- (2018) Paola Portillo-Sanchez et al. Journal of Diabetes
- Deciphering the Roles of PPARγ in Adipocytes via Dynamic Change of Transcription Complex
- (2018) Xinran Ma et al. Frontiers in Endocrinology
- Molecular pathways of nonalcoholic fatty liver disease development and progression
- (2018) Fernando Bessone et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- The Role of PPAR-δ in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor
- (2018) Yi Liu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
- (2018) Konstantin Kazankov et al. Nature Reviews Gastroenterology & Hepatology
- Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants
- (2018) Elizabeth R C Millett et al. BMJ-British Medical Journal
- The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond
- (2018) Pallavi R. Devchand et al. Frontiers in Pharmacology
- Current Concepts in Pediatric Nonalcoholic Fatty Liver Disease
- (2017) Sarah E. Fleet et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases
- (2017) Leon A Adams et al. GUT
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease
- (2017) Fernando Bril et al. HEPATOLOGY
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
- (2017) Parambir S. Dulai et al. HEPATOLOGY
- The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice
- (2017) Giuseppe Derosa et al. JOURNAL OF CELLULAR PHYSIOLOGY
- The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis
- (2017) Clair Crewe et al. JOURNAL OF CLINICAL INVESTIGATION
- Current and future pharmacological therapies for NAFLD/NASH
- (2017) Yoshio Sumida et al. JOURNAL OF GASTROENTEROLOGY
- Targeting hepatic macrophages to treat liver diseases
- (2017) Frank Tacke JOURNAL OF HEPATOLOGY
- Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
- (2017) Hannes Hagström et al. JOURNAL OF HEPATOLOGY
- Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
- (2017) Mukul R. Jain et al. LIVER INTERNATIONAL
- Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
- (2017) Anna M. Diehl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging
- (2017) Seong Min Kim et al. Oncotarget
- Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis
- (2017) Giovanni Musso et al. JAMA Internal Medicine
- Novel Anti-fibrotic Therapies
- (2017) Benita L. McVicker et al. Frontiers in Pharmacology
- Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
- (2017) Elena Filipova et al. Diabetes Therapy
- Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
- (2017) Elena Filipova et al. Diabetes Therapy
- Dynamic plasticity of macrophage functions in diseased liver
- (2017) Thomas Ritz et al. CELLULAR IMMUNOLOGY
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
- (2016) Nadira Ruzehaji et al. ANNALS OF THE RHEUMATIC DISEASES
- Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
- (2016) Joel T. Haas et al. Annual Review of Physiology
- Non-alcoholic fatty liver disease and risk of type 2 diabetes
- (2016) S. Lallukka et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications
- (2016) Byron J. Hoogwerf et al. DIABETES CARE
- Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease
- (2016) Silvio E. Inzucchi et al. DIABETES CARE
- Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
- (2016) Romina Lomonaco et al. DIABETES CARE
- Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor
- (2016) R. A. DeFronzo et al. DIABETES OBESITY & METABOLISM
- Role of MicroRNAs in NAFLD/NASH
- (2016) Gyongyi Szabo et al. DIGESTIVE DISEASES AND SCIENCES
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
- (2016) Alexandra Montagner et al. GUT
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Is the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases?
- (2016) Attila Pap et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications
- (2016) Sven M. Francque et al. JOURNAL OF HEPATOLOGY
- Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
- (2016) Giovanni Targher et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Pharmacological management of nonalcoholic fatty liver disease
- (2016) Diana Barb et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- NAFLD and diabetes mellitus
- (2016) Herbert Tilg et al. Nature Reviews Gastroenterology & Hepatology
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
- (2016) Walter N. Kernan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pioglitazone for Secondary Stroke Prevention
- (2016) Meng Lee et al. STROKE
- Prevalence of Prediabetes and Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease
- (2016) Kimberly P. Newton et al. JAMA Pediatrics
- Estradiol Inhibits Cytokine-Induced Expression of VCAM-1 and ICAM-1 in Cultured Human Endothelial Cells Via AMPK/PPARα Activation
- (2015) Xuhui Hou et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH)
- (2015) Aastha Jindal et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
- (2015) Paul Angulo et al. GASTROENTEROLOGY
- Ligand-activated PPARδ upregulates α-smooth muscle actin expression in human dermal fibroblasts: A potential role for PPARδ in wound healing
- (2015) Sun Ah Ham et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
- (2015) Stuart McPherson et al. JOURNAL OF HEPATOLOGY
- PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis
- (2015) Sven Francque et al. JOURNAL OF HEPATOLOGY
- NAFLD: A multisystem disease
- (2015) Christopher D. Byrne et al. JOURNAL OF HEPATOLOGY
- Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
- (2015) Michal Pawlak et al. JOURNAL OF HEPATOLOGY
- The PPAR-γ antagonist GW9662 elicits differentiation of M2c-like cells and upregulation of the MerTK/Gas6 axis: a key role for PPAR-γ in human macrophage polarization
- (2015) Gaetano Zizzo et al. Journal of Inflammation-London
- Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat–cholesterol–sugar diet model in mice
- (2015) Michal Ganz et al. Journal of Translational Medicine
- A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver Disease
- (2015) Giovanni Targher et al. Metabolic Syndrome and Related Disorders
- Fibrosis in Nonalcoholic Fatty Liver Disease: Mechanisms and Clinical Implications
- (2015) Paul Angulo et al. SEMINARS IN LIVER DISEASE
- Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells
- (2015) Ling Chen et al. Oncotarget
- Ectopic Fat, Insulin Resistance, and Nonalcoholic Fatty Liver Disease
- (2014) Christopher D. Byrne et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes
- (2014) Raymond E. Soccio et al. Cell Metabolism
- Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans
- (2014) M. Miriam Jacome-Sosa et al. CURRENT OPINION IN LIPIDOLOGY
- The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice
- (2014) Michal Pawlak et al. HEPATOLOGY
- Identification of fibronectin binding sites in dermatopontin and their biological function
- (2014) Aiko Kato et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
- (2014) Hannele Yki-Järvinen Lancet Diabetes & Endocrinology
- Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
- (2013) E. Zardi et al. CURRENT MEDICINAL CHEMISTRY
- Dual Peroxisome Proliferator-Activated Receptor / Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
- (2013) B. Cariou et al. DIABETES CARE
- A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)
- (2013) Rajendrakumar H. Jani et al. Diabetes Technology & Therapeutics
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2013) Bart Staels et al. HEPATOLOGY
- A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use
- (2013) Sihao Liu et al. NATURE
- PPARγ signaling and metabolism: the good, the bad and the future
- (2013) Maryam Ahmadian et al. NATURE MEDICINE
- Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors
- (2012) Michel Dietz et al. ChemMedChem
- Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
- (2012) C. Ortiz-Lopez et al. DIABETES CARE
- PPAR agonists for the treatment of cardiovascular disease in patients with diabetes
- (2012) J. P. H. Wilding DIABETES OBESITY & METABOLISM
- Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience
- (2012) D. E. Bonds et al. DIABETOLOGIA
- Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
- (2012) Kenneth Cusi GASTROENTEROLOGY
- Inflammasomes in liver diseases
- (2012) Gyongyi Szabo et al. JOURNAL OF HEPATOLOGY
- Protection from liver fibrosis by a peroxisome proliferator-activated receptor agonist
- (2012) K. Iwaisako et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia
- (2011) Yun-Jung Choi et al. ATHEROSCLEROSIS
- Roles of PPARs in NAFLD: Potential therapeutic targets
- (2011) Anne Tailleux et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin
- (2011) Harold E. Bays et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Inflammatory links between obesity and metabolic disease
- (2011) Carey N. Lumeng et al. JOURNAL OF CLINICAL INVESTIGATION
- Peroxisome proliferator-activated receptor-α agonist, Wy 14 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis
- (2011) Claire Z Larter et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
- (2011) Ralph A. DeFronzo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proline- and acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-activated receptor (PPAR ) activity
- (2011) F. Gachon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pioglitazone in the treatment of NASH: the role of adiponectin
- (2010) A. Gastaldelli et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
- (2010) T. M. E. Davis et al. DIABETOLOGIA
- Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study
- (2010) M. Stepanova et al. GUT
- Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites
- (2010) Brent A. Neuschwander-Tetri HEPATOLOGY
- Role of Peroxisome Proliferator-activated Receptor δ/β in Hepatic Metabolic Regulation
- (2010) Sihao Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease
- (2010) Elisa Fabbrini et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome
- (2010) Renata Belfort et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Kupffer cell activation is a causal factor for hepatic insulin resistance
- (2009) Nicolas Lanthier et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Identification of a Physiologically Relevant Endogenous Ligand for PPARα in Liver
- (2009) Manu V. Chakravarthy et al. CELL
- Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus
- (2009) Rutger W. van der Meer et al. CIRCULATION
- Harmonizing the Metabolic Syndrome
- (2009) K.G.M.M. Alberti et al. CIRCULATION
- Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
- (2009) Vlad Ratziu et al. HEPATOLOGY
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
- (2009) Philip D Home et al. LANCET
- Transcriptional profiling reveals divergent roles of PPARα and PPARβ/δ in regulation of gene expression in mouse liver
- (2009) Linda M. Sanderson et al. PHYSIOLOGICAL GENOMICS
- Comparative Analysis of Gene Regulation by the Transcription Factor PPARα between Mouse and Human
- (2009) Maryam Rakhshandehroo et al. PLoS One
- Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice
- (2008) Elizabeth E. Girroir et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance
- (2008) Justin I. Odegaard et al. Cell Metabolism
- Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial
- (2008) Vlad Ratziu et al. GASTROENTEROLOGY
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
- (2008) Guruprasad P. Aithal et al. GASTROENTEROLOGY
- Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
- (2008) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Hepatic Overexpression of Hormone-sensitive Lipase and Adipose Triglyceride Lipase Promotes Fatty Acid Oxidation, Stimulates Direct Release of Free Fatty Acids, and Ameliorates Steatosis
- (2008) Brendan N. Reid et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Suppression of Pro-inflammatory Adhesion Molecules by PPAR-δ in Human Vascular Endothelial Cells
- (2007) Yanbo Fan et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now